Florham Park, New Jersey, United States
Experienced Executive Officer with a successful track record in the pharmaceutical and biotechnology industry. Corporate leadership and hands on skills in commercial operations, strategic development, marketing, sales, and business development, and P&L. Demonstrated record of achievement in leadership, developing and executing strategies which have led companies and products to rapid growth. A tested and trusted leader who builds and coaches collaborative teams to success in the across the organization. Consistent record of superior performance, validated by measurable results and advancement throughout career. Extensive knowledge of pharmaceutical, devices and diagnostic industry dynamics, both locally as well as globally. Proven areas of expertise: M&A, Capital Raise, P&L ownership, Marketing & General Management, Global Marketing, Strategic Planning, Market Development, Product Development – Launch - Management, Marketing Communications, Commercialization of New Products, Sales processes / Targeting models, Key Opinion Leader Management, Multi-Channel Marketing, Team Development & Leadership, Sales, Budget Management. This experience has also given him in depth strategic understanding of multiple payor models including: pharmacy, buy-and-bill, CMS, J-Code, C-Code, Specialty Pharmacy, Specialty distribution, consignment, patient benefits/HUB. Demonstrated ability to adapt within the models to ensure access and coverage. Therapeutic experience in: Allergy, AntiFungals, Anti-biotics, Condyloma, Contraception, HAE (orphan), Hepatic Encephalopathy, Hypertension, HRT, IBS-D, GI, Incontinence, Neuro/Psych, Oncology Diagnostics, Onychomycosis (anti-fungals), Ophthalmology (front and back), Pain, Rare disease, Ulcerative Colitis, and OTC Nicotine Gum (including private labeling).
UTILITY therapeutics is focused on developing and commercializing antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. Reporting directly to the Board of Directors – responsible for advancing an antibiotic portfolio to NDA, commercialization, capital raise, business development, and securing banking advisor. • Managed the development of PIVYA NDA and FDA interactions which led to FDA approval of PIVYA • PIVYA is now the 1st New FDA approved antibiotic for uncomplicated UTIs in over 20 years • Directed full M&A lifecycle, culminating in a strategic acquisition that maximized shareholder value
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 3 FDA-approved sustained-release treatments in ophthalmology. • Hired and launched new team of Strategic Account Managers to expand utilization of DEXYCU and YUTIQ • Launched innovative reimbursement program to minimize financial exposure for ASCs, PEs, and PM Companies • Developed detailed analytics to identify key areas of growth for DEXYCU
• Built Commercial infrastructure inclusive of Marketing, Sales, Sales Ops, Analytics and Trade personnel • Developed strategy and executed the launches of 2 innovative Ophthalmic brands in Q1, 2019 in 2 distinct TAs with 2 distinct sales forces • Manage Manufacturing, Distribution, and forecasting Demand for the organization